红杉中国多轮押注，这家医疗器械细分龙头企业IPO了

Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. (Beixin Life) officially listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on February 5, 2026, marking a significant listing case after the resumption of the fifth set of listing standards [1][15]. Company Overview - Beixin Life was founded on December 11, 2015, by Dr. Song Liang, a biomedical engineering expert, in collaboration with seasoned professionals from the medical industry [2][17]. - The company focuses on the cardiovascular precision intervention field, addressing clinical needs in coronary artery disease, peripheral vascular disease, and atrial fibrillation [5][19]. - Beixin Life has evolved from a single-product company to a comprehensive medical device enterprise with 11 commercialized products and 6 products under research, covering five major categories: IVUS systems, FFR systems, vascular access products, shockwave balloon therapy systems, and electrophysiological solutions [5][19]. Product Innovation - The FFR system, Beixin Life's first breakthrough product, received approval from the National Medical Products Administration in 2020, becoming the first domestically produced gold standard FFR product [6][20]. - The IVUS system, launched in July 2022, is China's first domestically developed 60MHz high-definition IVUS product and the fastest in terms of retraction speed and cross-sectional imaging speed globally [6][20]. - As of June 30, 2025, Beixin Life holds 185 authorized patents domestically and internationally, including 86 invention patents and 14 PCT international patent applications [6][20]. Financial Performance - From 2022 to 2024, Beixin Life's revenue is projected to grow from 92 million yuan to 317 million yuan, with a year-on-year growth of 72% in 2024, primarily driven by the rapid sales growth of the IVUS system [7][21]. - The company's net profit attributable to shareholders is expected to improve from a loss of 290 million yuan in 2022 to a loss of 4.4 million yuan in 2024, with a profit of 20.61 million yuan in the first quarter of 2024 [7][21]. - By the end of 2024, Beixin Life's products had entered approximately 1,000 hospitals globally, covering 30 provinces and cities in China, and expanding to over ten overseas countries, with overseas revenue reaching 38.83 million yuan, a nearly 160% increase year-on-year [7][21]. Investment and Support - Sequoia China has participated in at least five rounds of financing for Beixin Life, holding 10.1759% of the company's shares, making it the second-largest shareholder [8][9][23]. - The support from investors has been crucial for Beixin Life's development, with a focus on the cardiovascular precision diagnosis market [8][9][23]. Market Outlook - The innovative medical device industry is a key strategic emerging industry supported by national policies, with the cardiovascular intervention device market expected to grow at a compound annual growth rate of 10.2%, projected to exceed 90 billion yuan by 2026 [11][26]. - Despite the promising outlook, Beixin Life faces challenges such as price declines due to centralized procurement and competition from both domestic and international companies in the IVUS and FFR markets [12][26]. - The listing of Beixin Life signifies the transition of Chinese innovative medical device companies from technology followers to strong competitors in the global market [12][27].